Ipsen writes down $725M after largest-ever acquisition, trial woes

Less than one year after Ipsen SA made its largest-ever acquisition, the company has written down most of the deal ’s value as a loss.  Ipsen spent $1 billion last year to acquire Canadian startup Clementia Pharmaceuticals Inc. and its leading rare disease drug candidate. But the drug giant, which is based in France and has its U.S. headquarters in Cambridge, recorded a $725 million impairment loss on the de al in its year-end financial report, resulting in a $54 million net loss for Ipsen.  The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news